Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial.
Saved in:
| Title: | Efficacy, Safety, and Pharmacodynamic Effects of the Bruton's Tyrosine Kinase Inhibitor Fenebrutinib (GDC-0853) in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Trial. |
|---|---|
| Authors: | Isenberg D; University College London, London, UK., Furie R; Northwell Health, Great Neck, New York., Jones NS; Genentech, Inc., South San Francisco, California., Guibord P; Hoffmann-La Roche, Mississauga, Ontario, Canada., Galanter J; Genentech, Inc., South San Francisco, California., Lee C; Genentech, Inc., South San Francisco, California., McGregor A; Genentech, Inc., South San Francisco, California., Toth B; Genentech, Inc., South San Francisco, California., Rae J; Genentech, Inc., South San Francisco, California., Hwang O; Genentech, Inc., South San Francisco, California., Desai R; Genentech, Inc., South San Francisco, California., Lokku A; Hoffmann-La Roche, Mississauga, Ontario, Canada., Ramamoorthi N; Genentech, Inc., South San Francisco, California., Hackney JA; Genentech, Inc., South San Francisco, California., Miranda P; Centro Estudios Reumatologicos, Santiago, Chile., de Souza VA; Centro Mineiro de Pesquisas, Juiz de Fora, Brazil., Jaller-Raad JJ; Centro de Reumatologia y Ortopedia, Cimedical, Barranquilla, Colombia., Maura Fernandes A; Mario Covas Hospital, Santo Andre, Sao Paulo, Brazil., Garcia Salinas R; Hospital Italiano de La Plata, Buenos Aires, Argentina., Chinn LW; Genentech, Inc., South San Francisco, California., Townsend MJ; Genentech, Inc., South San Francisco, California., Morimoto AM; Genentech, Inc., South San Francisco, California., Tuckwell K; Genentech, Inc., South San Francisco, California. |
| Source: | Arthritis & rheumatology (Hoboken, N.J.) [Arthritis Rheumatol] 2021 Oct; Vol. 73 (10), pp. 1835-1846. Date of Electronic Publication: 2021 Aug 24. |
| Publication Type: | Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
| Journal Info: | Publisher: Wiley Country of Publication: United States NLM ID: 101623795 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 2326-5205 (Electronic) Linking ISSN: 23265191 NLM ISO Abbreviation: Arthritis Rheumatol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2326-5205 |
|---|---|
| DOI: | 10.1002/art.41811 |
